



FIG. 1

GL1208 gallbladder cancer xenograft model

FIG. 2A



CR3056 colorectal cancer xenograft model



Tucatinib Mediated Inhibition of HER2 V777L Mutant
Phospho-ErbB2/HER2
150
100
50
0
0.0001
0.001
0.01
0.1
1
10
µM
IC50
0.07122

FIG. 2B





FIG. 3

GA2140 gastric cancer xenograft model

FIG. 4



GA6210 gastric cancer xenograft model



Tucatinib Activity in LU-5239 HER2 L755S Mutant NSCLC PDX
Vehicle Control
Tucatinib 50 mg/kg BID
Trastuzumab 20 mg/kg QW
Tucatinib 50 mg/kg BID + trastuzumab 20 mg/kg QW
Tumor Volume (mm³) ± SEM
3000
2000
1000
0
0
10
20
30
Study Day

FIG. 5A



Tucatinib Mediated Inhibition of HER2 L755S Mutant
Phospho-erbB2/HER2
300
200
100
0
0.0001
0.001
0.01
0.1
1
10
µM
IC50
0.01775

FIG. 5B



Tucatinib Activity in CR-5085 HER2
L755S Mutant Colorectal PDX
Vehicle Control
Tucatinib 50 mg/kg BID
Trastuzumab 20 mg/kg QW
Tucatinib 50 mg/kg BID
+ trastuzumab 20 mg/kg
QW
Tumor Volume (mm3) ± SEM
600
400
200
0
0
10
20
30
Study Day

FIG. 6



Tucatinib Activity in HER2
G776insYVMA Mutant NSCLC PDX
Vehicle Control
Tucatinib 50 mg/kg BID
Trastuzumab 20 mg/kg QW
Tucatinib 50 mg/kg BID
+ trastuzumab 20 mg/kg QW
Tumor Volume (mm3) + SEM
1000
800
600
400
200
0
0
10
20
30
40
50
Study Day

FIG. 7A



Effect of Tucatinib on YVMA 776-779 ins
% Control
150
100
50
0
0.0001
0.01
1
μM
IC50
0.004369

FIG. 7B